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Abstract : Linagliptin is an anti-diabetic drug and the only bile-excreted dipep-
tidyl peptidase-4 inhibitor.  Malnutrition-inflammation-atherosclerosis syndrome 
is an important prognostic factor for hemodialysis patients, and we previously 
reported anti-inflammatory effects of linagliptin in hemodialysis patients with 
diabetes.  Inflammation can accelerate oxidative stress, vasoconstriction, and 
platelet aggregation.  However, few studies have investigated the pleiotropic 
effects of linagliptin treatment on inflammation in hemodialysis patients.  In 
this study, we have extended our previous investigations of these effects in a 
longer and more thorough follow-up of hemodialysis patients with diabetes.  We 
examined 20 hemodialysis patients with diabetes who were not receiving oral 
diabetes drugs or insulin therapy and who exhibited inadequate glycemic control 
（glycated albumin levels＞ 20％）.  Linagliptin （5 mg） was administered daily, and 
we evaluated the patients’ superoxide dismutase, 8-hydroxydeoxyguanosine, nitric 
oxide, nitric oxide synthase, and asymmetric dimethylarginine levels in serum at 
baseline and after 1, 3, and 6 months of treatment.  After 6 months of treatment, 
superoxide dismutase levels had signicantly decreased from 8.8 ± 0.5 U/ml to 7.0
± 0.5 U/ml.  Nitric oxide synthase levels were signicantly increased at 3 and 6 
months （maximum, 94.2 ± 13.2 µg/ml ; baseline, 31.6 ± 5.5 µg/ml）.  After 3 months 
of treatment, nitric oxide levels had signicantly increased from 64.5 ± 6.6 µmol/
l to 104 ± 15.4 µmol/l, and remained significantly elevated at 6 months.  Asym-
metric dimethylarginine and 8-hydroxydeoxyguanosine levels did not change during 
the 6-month treatment course, and no patients exhibited hypoglycemia or other 
signicant adverse effects.  Linagliptin treatment signicantly changed various mark-
ers of inflammation relevant to the atherosclerosis in malnutrition-inflammation-
atherosclerosis syndrome.  Therefore, linagliptin monotherapy has pleiotropic effects 
on inflammation in hemodialysis patients with diabetes, and may improve their 
prognosis.
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Introduction
　Hemodialysis （HD） patients have a high prevalence of protein-energy malnutrition, inamma-
tion, and atherosclerotic cardiovascular disease.  Since these three pathophysiological conditions 
can occur concomitantly in HD patients via the actions of pro-inammatory cytokines, they are 
referred to together as malnutrition-inflammation-atherosclerosis syndrome （MIA syndrome）. 
MIA syndrome is an important prognostic factor for HD patients1）.  In addition, diabetes mel-
litus can induce end-stage renal disease and promote the inammatory status in MIA syndrome. 
Although insulin injections are central to the treatment of HD patients, eyesight failure due to 
diabetic retinopathy and aging-associated dementia can contraindicate multiple daily insulin injec-
tions2）.  Moreover, among HD patients, many oral anti-diabetic drugs induce critical side effects, 
such as hypoglycemia and lactic acidosis.  Therefore, new oral anti-diabetic drugs with fewer side 
effects are needed for HD patients.  In this context, dipeptidyl peptidase-4 （DPP-4） inhibitors 
are well tolerated, have a lower incidence of hypoglycemia, and provide a good safety prole.
　Linagliptin is an anti-diabetic drug that is also the only bile-excreted DPP-4 inhibitor, thus it 
does not require a reduced dose in HD patients with diabetes.  We previously reported the anti-
inammatory effects of linagliptin in HD patients with diabetes, wherein after initiating linagliptin 
treatment, the levels of prostaglandin E2, interleukin 6, and glycated albumin （GA） decreased sig-
nicantly, whereas levels of glucagon-like peptide-1 （GLP-1） increased signicantly3）.  Interestingly, 
inammation is known to accelerate oxidative stress, vasoconstriction, and platelet aggregation, all 
of which are related to the atherosclerosis in MIA syndrome.  Consequently, linagliptin therapy 
also reduces the risk of cardiovascular and cerebrovascular diseases （CCV）4）, which are associated 
with systemic atherosclerosis and related prognostic factors.  Given the anti-inammatory effects 
of linagliptin, this drug may suppress oxidative stress, vasoconstriction, and platelet aggregation, 
although very few studies have investigated such pleiotropic effects of linagliptin.
　The present study was undertaken to investigate the pleiotropic effects of linagliptin monother-
apy treatment on inammation in HD patients with diabetes, in an extension and more thorough 
follow-up of our previous study 3）.  
Methods
Patients
　For the present study, we included 20 HD patients （16 men, 65.5 ± 2.8 years old） with diabe-
tes and inadequate glycemic control （GA levels of ＞ 20％） who were also adhering to diet and 
exercise therapy.  We selected GA to reect glycemic control, as hemoglobin A1c （HbA1c, the 
more common parameter） is articially reduced in HD patients5-7）.  Among the 20 patients that 
we included, 4 had a history of insulin therapy, 8 were taking other oral anti-diabetic drugs, and 
8 had been treated with both insulin and other oral anti-diabetic drugs.  However, their therapy 
was subsequently discontinued before or after the initiation of maintenance dialysis therapy, with 
an average washout period of ＞ 2 years.  Thus, at the start of the study, no patient was using 
a prescribed oral anti-diabetic drug or receiving insulin injections, and their glycemic control had 
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become inadequate.  In addition, no patient was taking non-steroidal anti-inammatory drugs or 
allopurinol.  During the treatment period, the patients received a once-daily oral dose of lina-
gliptin （5 mg）.  The ethics committee of Saiyu Soka Hospital approved the study design, and all 
patients provided informed consent.
　
Efcacy
　The following efcacy parameters were examined at baseline and after 1, 3, and 6 months of 
treatment : oxidative stress （superoxide dismutase ［SOD］ activity and high sensitivity 8-hydroxy-
deoxyguanosine ［8-OHdG］ levels） and vasodilatation and platelet aggregation dysfunction factors 
（nitric oxide ［NO］, nitric oxide synthase ［NOS］, and asymmetric dimethylarginine ［ADMA］ 
levels）.  
　
Safety assessments
　To assess safety through this study, we undertook monitoring for all adverse events including 
hypoglycemic events, which were assessed via blood glucose measurements.  To address possible 
hypoglycemic events, a 24-h treatment support system was made available to all patients, allowing 
them to receive immediate treatment if they experienced any symptoms of hypoglycemia.  More-
over, participants underwent capillary glucose monitoring before commencing their HD treatment. 
Participants also underwent regular hematological and blood biochemical assessments and evalua-
tions of their vital signs and physical condition.
　
Blood samples
　For the present study, we evaluated the same blood samples that were used in our previous 
study 3）.  These blood samples were taken from the arterial side of the arteriovenous fistula, 
before the start of HD treatment and 1-2 h before eating.  Caution was exercised to prevent 
hemolysis of the samples ; the plasma was obtained via centrifugation and was subsequently 
stored at -70°C until the analysis.  
　
Measurement of parameters
　SOD activity was measured using a batched-reagent set at a single laboratory （SRL Labora-
tory, Hachioji, Tokyo, Japan） via an improved nitrite method, which estimates the activity based 
on the decreasing rate of nitrite that is produced by hydroxylamine and superoxide anions. 
The patients’ 8-OHdG levels were measured using the high-sensitivity 8-OHdG enzyme-linked 
immunosorbent assay （ELISA ; Japan Institute for the Control of Aging, Nikken SEIL Co., Ltd., 
Fukuroi, Shizuoka, Japan）, which evaluates 8-OHdG as a product of oxidized DNA formed by 
hydroxyl radicals, singlet oxygen, and direct photodynamic action.  NO levels were measured 
using the QuantiChromTM Nitric Oxide Assay Kit （BioAssay Systems, Hayward, CA, USA）, 
which measures NO production after the reduction of nitrate to nitrite via the improved Griess 
method.  NOS activity was measured using the EnzyChromTM Nitric Oxide Synthase Assay Kit 
（BioAssay Systems, Hayward, CA, USA）, which uses a 2-step process, whereby NOS produces 
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NO that is subsequently detected and quantied.  ADMA levels were measured using reverse-
phase high-performance liquid chromatography with AccQ Tag amino acid analysis.  This method 
uses 6-aminoquinolyl-N-hydroxysuccinimidyl carbamate （a derivatizing agent）, which has a deriva-
tized amino acid yield of 100％8）.  
　
Statistical analysis
　JMP statistical software （version 10 ; SAS Institute, Cary, NC, USA） was used for all statistical 
analyses, and the results are presented as mean ± standard error.  Signicance was tested using 
the paired t-test, and differences with a P-value of ＜ 0.05 were considered statistically signicant.
Results
Patient history
　Table 1 details the baseline characteristics of the 20 patients included in this study.  Six 
patients were smokers, nine were receiving antiplatelet drugs, two were receiving vasodilator 
drugs, six were receiving 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, and three 
patients were receiving angiotensin receptor blockers.  Each patient had received treatment for 
type 2 diabetes prior to the start of maintenance dialysis therapy, with a mean treatment period 
of 10.4 ± 2.1 years.  Dialysis treatment was conducted three times per week in 4-h sessions, with 
a mean treatment duration of 6.0 ± 1.9 years.  During HD treatment, the mean blood ow was 
201.0 ± 4.9 ml / min （range, 160-250 ml / min）, the mean volume of the dialysate was 515.0 ±
10.9 ml / min （range, 500-700 ml / min）, the mean dialysis time was 4.1 ± 0.1h （range, 4-4.5 h）, the 
Table 1.　Baseline patient characteristics
Parameter Mean ± standard error 
Age 65.5 ± 2.8
Sex （male） 16
Diabetes treatment period （years） 10.4 ± 2.1
Dialysis treatment period （years） 6.0 ± 1.9
Body mass index （kg / m2） 21.9 ± 0.8
Smoking （n） 6
Antiplatelet drugs （n） 9
Vasodilator drugs （n） 2
HMG-CoA reductase inhibitors （n） 6
Angiotensin receptor blockers （n） 3
Hemoglobin （g / dl） 10.6 ± 0.3
Albumin （g / dl） 3.5 ± 0.1
Potassium （mEq / l） 4.4 ± 0.2
Phosphorus （mg / dl） 4.9 ± 0.2
Urea nitrogen （mg / dl） 55.8 ± 3.6
Serum creatinine （mg / dl） 9.2 ± 0.5
High-sensitivity C-reactive protein （mg / dl） 0.2 ± 0.1
HMG-CoA＝ hydroxymethylglutaryl coenzyme A
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mean membrane area was 1.8 ± 0.1 m2 （range, 1.5-2.1 m2）, and the total glucose concentration in 
the dialysates was 100 mg / dl.  
　
Effect of linagliptin on SOD, NO, and NOS levels
　The patients’ SOD levels decreased significantly from 8.8 ± 0.5 U / ml at baseline to 7.0 ±
0.5 U / ml at 6 months after starting linagliptin （Fig. 1）.  In contrast, the patients’ NO levels 
increased signicantly from 64.5 ± 6.6 µmol / l at baseline to 104 ± 15.4 µmol / l at 3 months after 
starting linagliptin （Fig. 2）, along with their NOS levels, which reached a maximum value of 94.2
± 13.2 µg / ml （vs. 31.6 ± 5.5 µg / ml at baseline） at 6 months （Fig. 3）.  There were no changes in 
the levels of ADMA and 8-OHdG （Table 2）.  
　
No adverse effects of linagliptin treatment
　Hypoglycemia is a potential side effect of diabetes therapy, although a meta-analysis of clini-
cal trial data revealed that only a small number of hypoglycemic events were associated with 
vildagliptin and sitagliptin treatment （other DPP-4 inhibitors）9）.  Notably, no patient exhibited 
hypoglycemia or other signicant adverse effects over the 6-month course of the present study.
Discussion
　Inammation is an important prognostic factor for HD patients, and the pleiotropic effects of 
inammation are relevant when treating HD patients.  Herein, we conrmed and further inves-
tigated these effects, showing that linagliptin treatment signicantly decreased the levels of SOD 
over a 6-month follow up, while increasing the levels of NO and NOS.
　In our previous report on the anti-inflammatory effects of linagliptin in HD patients with 
Fig. 1.  Superoxide dismutase （SOD） levels before 
and after starting linagliptin. The patients’ 
SOD levels decreased significantly from 8.8 ±
0.5 U / ml at baseline to 7.0 ± 0.5 U / ml after 
6 months of linagliptin therapy.  Values are 
expressed as mean ± standard error.  ＊P ＜
0.05.
Fig. 2.  Nitric oxide （NO） levels before and after 
starting linagliptin.  The patients’ NO levels 
increased significantly from 64.5± 6.6 µmol / l at 
baseline to 104 ± 15.4 µmol / l after 3 months 
of linagliptin therapy, and the NO levels 
remained significantly elevated at 6 months. 
Values are expressed as mean ± standard 
error.  ＊P＜ 0.05.
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diabetes3）, we proposed four potential mechanisms underlying such effects : increased GLP-
1, suppression of DPP-4 （CD26）, an effect of the xanthine-related skeletal systems, or an anti-
diabetic effect.  In the present study, we conrmed the anti-inammatory effects of linagliptin, 
and additionally observed a signicant decrease in the levels of oxidative stress marker, SOD.  In 
this context, the increased levels of GLP-1 could have both anti-oxidant and anti-inammatory 
effects10-12）.  In addition, DPP-4 is expressed as CD26 on the membranes of various cells, includ-
ing leukocytes, where it acts as an inammatory mediator, with roles in T-cell activation, DNA 
synthesis, cell proliferation, cytokine production, and signaling activation.  Therefore, oxidative 
processes might also be modulated by DPP-4 inhibition13，14）, and a recent clinical trial involving a 
single daily dose of linagliptin （5 mg） administered to patients with diabetes showed that DPP-4 
was inhibited by ＞ 80％ for 24 h after treatment15）.  Indeed, linagliptin exhibited stronger inhibi-
tory activity and selectivity for DPP-4 compared to other inhibitors tested.  Furthermore, among 
the nine types of DPP-4 inhibitors, linagliptin is the only one with a xanthine-based skeletal 
structure, and the pharmacological mechanisms underlying the anti-oxidant and anti-inammatory 
activities associated with such a molecular structure remain unclear16）.  Thus, it is possible that 
this structural nature of linagliptin suppresses the degradation of cyclic adenosine monophosphate 
（cAMP） via phosphodiesterase inhibition （thereby increasing intracellular cAMP concentration）. 
Fig. 3.  Nitric oxide synthase （NOS） levels before and 
after starting linagliptin.  The patients’ NOS 
levels increased significantly at 3 months after 
starting linagliptin （57.2 ± 11.3 µg / ml vs. 31.6
± 5.5 µg / ml）, and the NOS levels increased 
further to 94.2 ± 13.2 µg / ml after 6 months 
of linagliptin therapy.  Values are expressed 
as mean ± standard error.  ＊P＜ 0.05.
Table 2.　The response of oxidative stress markers to linagliptin therapy
Parameter Before therapy 1 month 3 months 6 months
ADMA （nmol / ml） 0.64 ± 0.03 0.66 ± 0.03 0.69 ± 0.04 0.70 ± 0.03
8-OHdG （ng / ml） 0.34 ± 0.02 0.37 ± 0.02 0.32 ± 0.02 0.38 ± 0.03
ADMA＝ asymmetric dimethylarginine; 8-OHdG＝ high sensitivity 8-hydroxydeoxyguanosine
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Finally, hyperglycemia induces monocytes to release interleukin 6 （an inammatory cytokine） via 
protein kinase C induction17）, and also stimulates pro-inammatory cytokine production via c-Jun 
N-terminal kinase in monocytic THP-1 cells18）.  We have previously conrmed the antidiabetic 
effects of linagliptin in the patients of this study3）, nding that the GA levels, a parameter of 
glycemic control, were signicantly decreased after starting linagliptin therapy, and there was very 
little difference in the effects of linagliptin therapy among the patients.  Therefore, improved 
glycemic control may help prevent oxidative stress in HD patients with diabetes, although further 
studies among HD patients are needed to conrm the anti-oxidant effect of linagliptin.  
　In patients with type 2 diabetes, GLP-1 promotes an eNOS-mediated increase in vasodilatation, 
and prevents tumor necrosis factor α-induced expression of plasminogen activator inhibitor-1 
and vascular cell adhesion molecule-1 in vascular endothelial cells19，20）.  However, little is known 
about how linagliptin affects vasodilatation and platelet aggregation dysfunction in HD patients 
with diabetes.  In our previous study, GLP-1 levels increased 2.5-fold after linagliptin treatment3）, 
and NO （which promotes vasodilatation and platelet aggregation dysfunction） increased with 
increasing NOS levels in the present study.  In addition, ADMA （an endogenous NOS inhibi-
tor） is dependent on GLP-1 receptor signaling21）, and the absence of any signicant increase in 
ADMA levels in the present study might have contributed to the increased levels of NO.
　Oxidative stress, vasodilatation, and suppression of platelet aggregation are other important 
atherosclerosis-related factors.  Therefore, the decreased SOD levels and increased NO and NOS 
levels observed herein might also reect an anti-atherosclerotic effect of linagliptin treatment22，23）. 
Peripheral arterial disease results from systemic atherosclerosis24）, and is an important prognostic 
factor for HD patients25）.  In this context, the ankle brachial pressure index （ABI） is particu-
larly useful in functionally evaluating peripheral arterial disease, and the rate of ABI decline 
predicts cardiovascular mortality in HD patients26）.  Previously, we used this index in comparing 
a cohort of 20 HD patients after 2 years of linagliptin treatment （the linagliptin group） with 
20 HD patients with diabetes who received once-daily doses of 6.25 mg alogliptin （the alogliptin 
group）.  Our unpublished results revealed a decrease in ABI from 0.97 ± 0.03 to 0.92 ± 0.07 in 
the linagliptin group, compared to that in the alogliptin group from 0.97 ± 0.05 to 0.83 ± 0.05.  In 
addition, signicantly fewer patients who received linagliptin （n＝ 6） showed a decrease in ABI, 
compared to the patients who received alogliptin （n＝ 14, P＜ 0.05）.  This difference suggests 
that not only does linagliptin have anti-atherosclerotic effects, but that such effects are stronger 
than those exerted by alogliptin.
　This study has several important limitations that should be considered when interpreting our 
results.  First, the present study did not include a control group and it included only a small 
number of participants.  However, as none of the patients were receiving diabetic drugs before 
or after the initiation of maintenance dialysis therapy, any improvement that we observed in 
the parameters was likely related to the linagliptin treatment.  Second, we did not observe any 
change in the levels of 8-OHdG （an oxidative stress marker） during the linagliptin treatment, 
suggesting that the anti-oxidant effect of linagliptin was not systemic.  However, as SOD is the 
enzyme that catalyzes the conversion of superoxide into oxygen and hydrogen peroxide, the anti-
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oxidant effects of linagliptin could be related to this activity.  Third, there are other markers of 
both oxidative stress and vasodilation, and in further studies we plan to evaluate the effects of 
linagliptin using various other physiological markers.  Moreover, we measured the enzyme activi-
ties of SOD and NOS in this study, but not the expression levels of their respective isozymes, 
and since each enzyme has three types of isozymes, future studies should address this issue.
　In conclusion, among HD patients with diabetes, linagliptin has pleiotropic effects on inamma-
tion that could signicantly affect patient prognosis.  We therefore recommend linagliptin mono-
therapy as a potential treatment strategy for HD patients with diabetes, given that inammation 
and atherosclerosis are important prognostic factors for these patients.
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